TWST · Twist Bioscience Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | $185.57M | $179.63M | $155.38M | $119.33M | $80.62M | $61.41M |
| Gross Profit | - | - | - | - | - | - |
| R&D | $80.28M | $90.85M | $106.89M | $120.31M | $69.07M | $43.01M |
| SG&A | $246.98M | $218.40M | $189.74M | $212.95M | $135.90M | $103.27M |
| Total Operating Expenses | $512.83M | $533.80M | $462.27M | $438.34M | $285.06M | $230.18M |
| D&A | $24.85M | $31.43M | $29.31M | $16.51M | $9.75M | $6.68M |
| Operating Income | ($136.26M) | ($220.83M) | ($217.16M) | ($234.78M) | ($152.73M) | ($140.08M) |
| Interest Expense | - | $29.0K | $5.0K | $80.0K | $367.0K | $787.0K |
| Income Tax | $719.0K | $560.0K | $1.15M | ($10.41M) | ($1.93M) | $382.0K |
| Net Income | ($77.67M) | ($208.73M) | ($204.62M) | ($217.86M) | ($152.10M) | ($139.93M) |
| EPS - Basic | ($1.30) | ($3.60) | ($3.60) | ($3.57) | - | - |
| EPS - Diluted | ($1.30) | ($3.60) | ($3.60) | ($3.57) | - | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $183.05M | $226.32M | $286.47M | $378.69M | $465.83M | $93.67M |
| Accounts Receivable | $57.02M | $34.90M | $44.06M | $40.29M | $28.55M | $26.38M |
| Inventory | $28.31M | $24.08M | $32.06M | $39.31M | $31.80M | $12.29M |
| Accounts Payable | $11.09M | $1.63M | $14.05M | $20.09M | $14.90M | $4.83M |
| Current Assets | $332.97M | $346.78M | $424.26M | $596.48M | $546.50M | $334.87M |
| Total Assets | $641.86M | $614.32M | $776.40M | $961.38M | $702.10M | $398.88M |
| Current Liabilities | $91.41M | $71.01M | $73.32M | $90.66M | $63.05M | $36.03M |
| Long-term Debt | - | - | - | - | - | $1.40M |
| Total Liabilities | $168.90M | $141.63M | $152.97M | $171.99M | $121.28M | $62.62M |
| Stockholders' Equity | $472.96M | $472.69M | $623.43M | $789.38M | $580.82M | $336.26M |
| Retained Earnings | ($1.32B) | ($1.24B) | ($1.03B) | ($828.42M) | ($610.55M) | ($458.45M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($47.63M) | ($64.09M) | ($142.47M) | ($124.39M) | ($112.24M) | ($142.25M) |
| Investing Cash Flow | ($24.76M) | ($3.07M) | $50.61M | ($232.93M) | $156.16M | ($114.65M) |
| Financing Cash Flow | $28.54M | $6.89M | $911.0K | $270.53M | $329.18M | $303.73M |
| CapEx | $28.00M | $5.08M | $27.78M | $101.86M | $27.06M | $9.87M |
| Free Cash Flow | ($75.63M) | ($69.17M) | ($170.25M) | ($226.24M) | ($139.31M) | ($152.12M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.97 | 0.33 | 0.83 | 1.04 | 0.92 | 1.09 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -12.1% | -34.0% | -26.4% | -22.7% | -21.7% | -35.1% |
| Return on equity | -16.4% | -44.2% | -32.8% | -27.6% | -26.2% | -41.6% |
| Return on invested capital | - | - | - | - | - | -32.8% |
| Liquidity | ||||||
| Current ratio | 3.64 | 4.88 | 5.79 | 6.58 | 8.67 | 9.29 |
| Quick ratio | 3.33 | 4.54 | 5.35 | 6.15 | 8.16 | 8.95 |
| Cash ratio | 2.00 | 3.19 | 3.91 | 4.18 | 7.39 | 2.60 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | 0.00 |
| Debt / Assets | - | - | - | - | - | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | -7614.9x | -43431.8x | -2934.7x | -416.1x | -178.0x |
| Equity multiplier | 1.36 | 1.30 | 1.25 | 1.22 | 1.21 | 1.19 |
| Liabilities / Assets | 0.26 | 0.23 | 0.20 | 0.18 | 0.17 | 0.16 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | 6.56 | 7.46 | 4.85 | 3.04 | 2.54 | 5.00 |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | 56d | 49d | 75d | 120d | 144d | 73d |
| Days payable outstanding | 22d | 3d | 33d | 61d | 67d | 29d |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 3.6x | 5.5x | 1.8x | 1.7x | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 38.3% | -1.7% | 7.5% | -53.7% | -9.0% | -28.7% |
| Net income growth (YoY) | 62.8% | -2.0% | 6.1% | -43.2% | -8.7% | -30.0% |
| EPS growth (YoY) | 63.9% | 0.0% | -0.8% | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -9.3% | 59.4% | 24.7% | -62.4% | 8.4% | -88.0% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 0.1% | -24.2% | -21.0% | 35.9% | 72.7% | - |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Twist Bioscience Corp against the 5 most active filers in the same SIC group.